HER2/Neu GP2 vaccine(Greenwich LifeSciences Inc/NuGenerex Immuno Oncology)

N/A

Report date: 2026/04/08 16:01:14

Base Information

Drug NameHER2/Neu GP2 vaccine(Greenwich LifeSciences Inc/NuGenerex Immuno Oncology)
Drug Alias NameGP2 peptide + GM-CSF vaccineGP2 peptide(NuGenerex Immuno-Oncology)HER2/Neu Peptide GP2HER2/neu peptide vaccineGLSI-100
ClassificationVaccines > Development/production technology > Synthetic peptide vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulantsReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandRomania +[9] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAntigen Express IncNorwell Inc
China Registration ClassN/A

Develop Information

Active CompaniesSan Antonio Military Medical CenterGreenwich LifeSciences Inc
Inactive CompaniesNorwell IncCancer Insight Llc
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A